An assessment by the statin intolerance panel: 2014 update

Journal of Clinical Lipidology

Volumn 8, Issue 3 SUPPL, 2014, Pages

  Guyton, John R ^a   Bays, Harold E ^b   Grundy, Scott M ^c   Jacobson, Terry A ^d  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug intolerance; Patient centered medicine; Statin adverse effects; Statin safety; Statins

Indexed keywords

ATORVASTATIN; BILE ACID SEQUESTRANT; EZETIMIBE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; MUSCLE ENZYME; NICOTINIC ACID; PHYTOSTEROL; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; STANOL ESTER;

ABNORMAL LABORATORY RESULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL DECISION MAKING; COGNITIVE DEFECT; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; HUMAN; METABOLIC DISORDER; METHODOLOGY; MORTALITY; MYALGIA; MYOPATHY; MYOSITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS; RISK REDUCTION; CARDIOVASCULAR DISEASES; CLINICAL TRIAL (TOPIC); COMPLICATION; DRUG TOLERANCE; EVIDENCE BASED MEDICINE; RISK FACTOR;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DRUG TOLERANCE; EVIDENCE-BASED MEDICINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RISK FACTORS;

EID: 84899883299     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2014.03.002     Document Type: Article

References (35)

1. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [e-pub ahead of print]. J Am Coll Cardiol. 2013. http://dx.doi.org/10.1016/j.jacc.2013.11.002.
2. G.H. Guyatt, A.D. Oxman, and G.E. Vist et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations BMJ 336 2008 924 926
3. P.A. James, S. Oparil, and B.L. Carter et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) JAMA 311 2014 507 520
4. A.M. Gotto Jr. Statins, cardiovascular disease, and drug safety Am J Cardiol 97 2006 3C 5C
5. M. Law, and A.R. Rudnicka Statin safety: a systematic review Am J Cardiol 97 2006 52C 60C
6. J.R. Guyton Benefit versus risk in statin treatment Am J Cardiol 97 2006 S95 S97
7. R. Chou, N. Aronson, and D. Atkins et al. AHRQ series paper 4: assessing harms when comparing medical interventions: AHRQ and the effective health-care program J Clin Epidemiol 63 2010 502 512
8. R.S. Scott, C.J. Lintott, and M.J. Wilson Simvastatin and side effects N Z Med J 104 1991 493 495
9. J. Shepherd Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety Eur Heart J 16 1995 5 13
10. R. Collins, J. Armitage, S. Parish, P. Sleigh, and R. Peto MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial Lancet 361 2003 2005 2016
11. J.A. Staffa, J. Chang, and L. Green Cerivastatin and reports of fatal rhabdomyolysis N Engl J Med 346 2002 539 540
12. D.J. Graham, J.A. Staffa, and D. Shatin et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs JAMA 292 2004 2585 2590
13. Cholesterol Treatment Trialists (CTT) Collaboration J.R. Emberson, P.M. Kearney, and L. Blackwell et al. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy PLoS One 7 2012 e29849
14. I. Ford, H. Murray, C.J. Packard, J. Shepherd, P.W. Macfarlane, S.M. Cobbe West of Scotland Coronary Prevention Study Group Long-term follow-up of the West of Scotland Coronary Prevention Study N Engl J Med 357 2007 1477 1486
15. Heart Protection Study Collaborative Group R. Bulbulia, L. Bowman, and K. Wallendszus et al. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial Lancet 378 2011 2013 2020
16. B.A. Parker, J.A. Capizzi, and A.S. Grimaldi et al. Effect of statins on skeletal muscle function Circulation 127 2013 96 103
17. J. Shepherd, G.J. Blauw, M.B. Murphy PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial Lancet 360 2002 1623 1630
18. MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience Eur Heart J 20 1999 725 741
19. MRC/BHF Heart Protection Study Collaborative Group J. Armitage, L. Bowman, R. Collins, S. Parish, and J. Tobert Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people BMC Clin Pharmacol 9 2009 6
20. E. Bruckert, G. Hayem, S. Dejager, C. Yau, and B. Begaud Mild-to-moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - the PRIMO study Cardiovasc Drugs Ther 19 2005 403 414
21. J.D. Cohen, E.A. Brinton, M.K. Ito, and T.A. Jacobson Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users J Clin Lipidol 6 2012 208 215
22. Clinical Practice Guidelines We Can Trust 2011 The National Academies Press Washington, DC
23. C.L. Bardes Defining "patient-centered medicine" N Engl J Med 366 2012 782 783
24. M.N. Walsh, A.A. Bove, R.R. Cross American College of Cardiology Foundation ACCF 2012 health policy statement on patient-centered care in cardiovascular medicine: a report of the American College of Cardiology Foundation Clinical Quality Committee J Am Coll Cardiol 59 2012 2125 2143
25. M.J. Barry, and S. Edgman-Levitan Shared decision making - pinnacle of patient-centered care N Engl J Med 366 2012 780 781
26. J.H. Levenstein, E.C. McCracken, I.R. McWhinney, M.A. Stewart, and J.B. Brown The patient-centred clinical method. 1. A model for the doctor-patient interaction in family medicine Fam Pract 3 1986 24 30
27. Expert Panel on Detection E, Treatment of High Blood Cholesterol in Adults Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
28. S.M. Grundy, J.I. Cleeman, C.N. Merz National Heart Lung, Blood Institute, American College of Cardiology Foundation, American Heart Association Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239
29. Goff DC, Jr., Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [e-pub ahead of print]. J Am Coll Cardiol. 2013. http://dx.doi.org/10.1016/j.jacc.2013. 11.005.
30. P. Amarenco, J. Bogousslavsky, A. Callahan 3rd Stroke Prevention by Aggressive Reduction in Cholesterol Levels I High-dose atorvastatin after stroke or transient ischemic attack N Engl J Med 355 2006 549 559
31. T.R. Pedersen, O. Faergeman, J.J. Kastelein Incremental Decrease in End Points Through Aggressive Lipid Lowering Study G High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial JAMA 294 2005 2437 2445
32. P.M. Ridker, E. Danielson, and F.A. Fonseca et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
33. D. Voora, S.H. Shah, and I. Spasojevic et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects J Am Coll Cardiol 54 2009 1609 1616
34. N.J. Stone Stopping statins Circulation 110 2004 2280 2282
35. A.J. Keating, K.B. Campbell, and J.R. Guyton Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy Ann Pharmacother 47 2013 398 404